Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Endo announced the launch of Belbuca (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It was initially approved by the Food and Drug Administration (FDA) in October 2015.
Belbuca is a mu-opioid receptor partial agonist and a kappa-opioid receptor antagonist, the first buprenorphine formulation developed as a buccal film. It utilizes BioDelivery’s BioErodible MucoAdhesive (BEMA) drug delivery technology. The patented delivery system allows buprenorphine to be efficiently delivered across the buccal mucosa.
RELATED: Does Opioid Use Increase Infection Risk in RA Patients?
Belbuca buccal film is CIII controlled substance. It is peppermint flavored and is available as 75mcg, 150mcg, 300mcg, 450mcg, 600mcg, 750mcg, 900mcg strengths in 60-count cartons.
For more information call (800) 462-3636 or visit Belbuca.com.
